From University of Tasmania - Research to Reality:
A new University of Tasmania collaboration is aiming to bring the complexities of in-house laboratory testing to the fingertips of those in the field.
In a move promised to revolutionise the way complex samples are carried out, a $5.2 million Australian Research Council Training Centre for Portable Analytical Separation Technologies (ASTech) was established late last year.
The University has partnered with Australian company Trajan Scientific and Medical and the Federal Government to explore new technologies which ultimately bring the laboratory to the sample.
"What if you could carry out a full suite of tests on a pin-prick droplet of blood … What if you could carry out tests on your smartphone?"
In response to the COVID-19 pandemic, the biopharmaceutical industry has leapt into action to better understand the disease and develop suitable vaccines and therapies.
Trajan Scientific and Medical and Synexa Life Sciences have developed and validated an innovative, market-leading SARS-CoV-2 serology assay, available for high-throughput clinical research applications, using Trajan's advanced precision microsampling technology to expedite therapy and vaccine development as well as large-scale screening, sero-surveillance and post-market surveillance initiatives.
Trajan Scientific and Medical’s hemaPEN® microsampling technology has been developed with extensive consultation and evaluation by leading analytical laboratories, clinicians and healthcare professionals.
This month, Trajan presents an exclusive interview with researcher Dr Michele Protti of Pharmaco-Toxicological Analysis, Bologna, Italy, on the future of microsampling and the critical role hemaPEN can play when used in therapeutic drug monitoring for optimal therapy personalization.